<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02315495</url>
  </required_header>
  <id_info>
    <org_study_id>ISSSAXA0015</org_study_id>
    <nct_id>NCT02315495</nct_id>
  </id_info>
  <brief_title>Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 Diabetes</brief_title>
  <official_title>Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zilin Sun</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongda Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study is designed to evaluate (i) the effects of saxagliptin, with or without
      acarbose, on gastric emptying, postprandial glycaemia, and plasma intact GLP-1, insulin,
      C-peptide and glucagon after a high carbohydrate meal, and (ii) whether the magnitude of the
      effects of saxagliptin and/or acarbose is related to the rate of gastric emptying, in
      patients with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood glucose concentrations at pre-defined intervals</measure>
    <time_frame>-60,-10,0,30,60,90,120,180min</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of incretin hormones at pre-defined intervals</measure>
    <time_frame>-60,-10,0,30,60,90,120,180min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of insulin at pre-defined intervals</measure>
    <time_frame>-60,-10,0,30,60,90,120,180min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of C-peptide at pre-defined intervals</measure>
    <time_frame>-60,-10,0,30,60,90,120,180min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of glucagon at pre-defined intervals</measure>
    <time_frame>-60,-10,0,30,60,90,120,180min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>half-emptying time (T50)</measure>
    <time_frame>0-180min</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>5 mg saxagliptin + 100 mg acarbose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acute dosing:
5 mg saxagliptin is given with water, 60 min before a test meal 100 mg acarbose is given with a test meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg saxagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acute dosing:
5 mg saxagliptin is given 60 min before a test meal,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg acarbose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acute dosing:
100 mg acarbose is given with a test meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin</intervention_name>
    <arm_group_label>5 mg saxagliptin + 100 mg acarbose</arm_group_label>
    <arm_group_label>5 mg saxagliptin</arm_group_label>
    <other_name>Onglyza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acarbose</intervention_name>
    <arm_group_label>5 mg saxagliptin + 100 mg acarbose</arm_group_label>
    <arm_group_label>100 mg acarbose</arm_group_label>
    <other_name>Glucobay</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes (World Health Organisation (WHO) criteria), managed by diet alone
             (i.e. no oral hypoglycaemic drugs or insulin)

          -  Body mass index (BMI) 20 - 40 kg/m2

          -  Age 18 - 70 years

          -  Males and post-menopausal females (to control for the effect of the menstrual cycle on
             gut hormone secretion)

          -  Glycated haemoglobin A1c (HbA1c) ≥ 6.0% and ≤ 7.9%

          -  Haemoglobin above the lower limit of the normal range (i.e. &gt;135g/L for men and 115g/L
             for women), and ferritin above the lower limit of normal (i.e. &gt;10mcg/L)

        Exclusion Criteria:

          -  Use of any medication that may influence gastrointestinal motor function, body weight
             or appetite

          -  Evidence of drug abuse, consumption of more than 20 g alcohol or 10 cigarettes on a
             daily basis

          -  History of gastrointestinal disease, including significant upper or lower
             gastrointestinal symptoms, pancreatitis, or previous gastrointestinal surgery (other
             than uncomplicated appendicectomy or cholecystectomy)

          -  Other significant illness, including epilepsy, cardiovascular or respiratory disease

          -  Autonomic nerve damage (as assessed by standardised cardiovascular reflex tests [36])

          -  Impaired renal or liver function (as assessed by calculated creatinine clearance &lt; 90
             mL/min or abnormal liver function tests (&gt; 2 times upper limit of normal range))

          -  Allergy to vildagliptin or any other 'gliptin'

          -  Donation of blood within the previous 3 months

          -  Participation in any other research studies within the previous 3 months

          -  Females who are pre-menopausal

          -  Inability to give informed consent

          -  Vegetarians
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zilin Sun, MD,PHD</last_name>
    <email>sunzilin1963@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Endocrinology, Zhongda Hospital. Institute of Diabetes, Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zilin Sun</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2014</study_first_submitted>
  <study_first_submitted_qc>December 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2014</study_first_posted>
  <last_update_submitted>July 20, 2015</last_update_submitted>
  <last_update_submitted_qc>July 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Zhongda Hospital</investigator_affiliation>
    <investigator_full_name>Zilin Sun</investigator_full_name>
    <investigator_title>MD, PhD of Department of Endocrinology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saxagliptin</mesh_term>
    <mesh_term>Acarbose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

